LGMN and Alzheimer disease: Together, these findings indicate that FMT‐BYHWD modulates gut microbiota to mitigate the overactivation of the C/EBPβ/AEP signaling pathway and reduce Tau phosphorylation, thus highlighting its potential as a therapeutic strategy for AD through gut–brain axis modulation.